Drugs /

intrathecal chemotherapy

Back to Drugs List

Overview

NCI Definition [1]:
Treatment in which anticancer drugs are injected into the fluid-filled space between the thin layers of tissue that cover the brain and spinal cord.

Clinical Trials

View Clinical Trials for intrathecal chemotherapy

Intrathecal chemotherapy has been investigated in 2 clinical trials, of which 2 are open and 0 are closed. Of the trials investigating intrathecal chemotherapy, 1 is phase 1 (1 open) and 1 is phase 2 (1 open).

BCR-ABL1 Fusion and t(9;22)(q34;q11) are the most frequent biomarker inclusion criteria for intrathecal chemotherapy clinical trials.

Acute lymphoblastic leukemia is the most common disease being investigated in intrathecal chemotherapy clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Intrathecal Chemotherapy
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating intrathecal chemotherapy and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

NCIT ID [1]:
C15750

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.